Anthropic Kicks Off IPO Roadshow: With an Expected Price Range of $70 to $78 Per Share, How Should We Interpret the Amount Raised?

New specific figures have emerged regarding Anthropic’s IPO process. On November 10, 2026, the company announced the launch of its IPO roadshow, with an expected price range of $70 to $78 per share, and has filed to list on the Nasdaq Global Select Market under the ticker symbol “ANT.” The announcement also noted that the relevant registration statement has not yet become effective.Anthropic Roadshow Announcement

For those following the AI industry, the most valuable aspect of this update is that the offering size and price range are now becoming clear. However, the roadshow, final pricing, completion of the offering, and the start of trading remain distinct milestones. Only by distinguishing between them can one truly understand where this transaction stands.

Compared to filing an S-1, what's new this time?

When Anthropic announced on October 26 that it had filed an S-1 registration statement, it stated that the number of shares to be offered and the price range had not yet been determined. An announcement on November 10 provided the proposed number of shares to be offered and the price range, and the company entered the roadshow phase. Therefore, the focus of this news is on the further clarification of the offering terms, rather than another announcement regarding the filing of an IPO application.Anthropic's S-1 Filing on October 26

Roadshows typically help companies and underwriters introduce their businesses to potential investors, discuss offering arrangements, and gather information on investor demand. The final price is influenced by market conditions, demand, and negotiations between the parties. The U.S. Securities and Exchange Commission’s investor education materials also note that the offering price may differ significantly from subsequent market trading prices.SEC Guidance on the IPO Pricing Process

Therefore, the range of $70 to $78 should accurately be referred to as the expected price range. The midpoint of the range, $74, is merely an arithmetic value and does not constitute a finalized offering price; the fact that a trading symbol has been applied for does not, by itself, prove that the listing has been completed.

825 million shares—we need to figure out who’s selling them

Under the plan announced by the company, a total of 825,000,000 Class A common shares are拟 to be issued, of which 801,351,354 shares will be sold by Anthropic and 23,648,646 shares will be sold by existing shareholders. The Company will not receive the proceeds from the sale of shares by existing shareholders. In addition, the Company expects to grant the underwriters a 30-day option to purchase up to an additional 123,750,000 shares.Offering Structure and Additional Share Purchase Options

These sets of figures correspond to different sources of funds. Proceeds from the company’s sale of shares and proceeds from existing shareholders’ sale of shares should not be combined to represent the total amount received by the company. Additional share purchase options should also be listed separately and should not be treated as if they had already been exercised and the proceeds received.

If we perform a scenario analysis based solely on the currently announced number of shares and price range—without taking into account the additional share purchase options or deducting underwriting discounts, commissions, and other offering expenses—we arrive at the following:

• The Proposed Offering as a Whole:825 million shares multiplied by $70 to $78 per share corresponds to a total value of approximately $57.75 billion to $64.35 billion.
• Section on the Company's Sale of Shares:801,351,354 shares, calculated using the same range, would yield gross proceeds of approximately $56.095 billion to $62.505 billion.
• Sale by Existing Shareholders:23,648,646 shares, calculated using the same range, would yield gross proceeds of approximately $1.655 billion to $1.845 billion.

The figures above are ranges estimated based on the proposed terms and do not represent the actual proceeds received upon completion of the financing. The Company’s net proceeds will be subject to the deduction of relevant expenses and will depend on the final offering arrangements. The additional 123,750,000 shares available for purchase represent 15% of the base offering size; this increase merely expands the potential offering size and does not imply that the final transaction will necessarily be expanded.

Issue size, company valuation, and operating revenue—these three factors provide the answers.

News reports often discuss “how much capital was raised” and “how much the company is worth” in the same breath, but the two concepts are based on different denominators. The offering size is calculated based on the number of shares sold in this round; equity valuation, however, requires taking into account the corresponding price and the total number of shares outstanding after the offering, and must also clarify whether potential dilutive factors—such as stock options and restricted stock—are included. Simply multiplying the 825 million shares in this offering by the price does not yield the valuation of the entire company.

Proceeds from fundraising are not the same as product sales revenue. The former reflects financing activities, while the latter stems from operating activities. Even if the transaction is completed as planned, these funds cannot be directly recorded as new revenue for Claude’s business, nor can it be concluded on that basis that the company has become profitable.

Similarly, the fact that existing shareholders sell a portion of their shares does not, in and of itself, indicate their attitude toward the company. To understand such arrangements, one must consider the seller’s identity, the percentage of shares held, the number of shares retained after the sale, and the specific disclosures. Categorizing all share sales as “bearish exits” overlooks important information embedded in the transaction structure.

For follow-up progress, which transaction nodes should be checked against?

During the roadshow, the most important new information to track is how the price, number of shares, and completion status change. These changes should be recorded separately to avoid having a single “IPO” heading cover multiple different stages.

• Registration Statement Effective:The effective date shall be determined by the date of explicit disclosure; the submission of documents or the commencement of a roadshow shall not be deemed to constitute the effective date.
• Final Terms of the Offering:Check the final offering price, the number of shares, and whether there have been any changes to the breakdown between shares sold by the company and those sold by existing shareholders.
• Start of Trading and Completion of the Offering:Confirm separately the announcement of the transaction's commencement and the completion of the offering; do not state the market quote as the amount of funds received by the company.
• Additional Share Purchase Option:Determine whether the options were actually exercised and, if so, to what extent, and then calculate the corresponding final issuance size.

If the total number of shares outstanding increases in the future, it is also important to examine the source of the additional shares. While both a company’s new share issuance and increased sales by existing shareholders will expand the transaction amount, they have different implications for the funds raised by the company. Behind the same total amount, there may be changes in price, changes in quantity, or both. Only by breaking these down can we understand how the financing arrangements have actually been adjusted.

The final prospectus typically includes information—such as the final price—that was not yet determined in the preliminary filing. Only when combined with the company’s subsequent announcements does it serve as the basis for updating the transaction figures; the price range provided during the roadshow cannot be used indefinitely in place of the final results.SEC Guidance on Preliminary and Final Prospectuses

The clear change at this stage is that Anthropic has moved from a phase where the offering size and price were undetermined to a roadshow phase with specific ranges. To understand this step, it is crucial to distinguish between the proposed terms, the calculated results, and the facts that have already occurred. This approach ensures that the scale of the transaction is not overlooked, while also preventing a funding plan from being prematurely treated as an IPO outcome.